Recombinant MAM from Faecalibacterium duncaniae exhibits a protective effect in DNBS-induced colitis

Area of Science:

• Gut microbiota and immunology
• Probiotic research and development
• Inflammatory Bowel Disease (IBD) therapeutics

Background:

• Faecalibacterium duncaniae A2-165 is a next-generation probiotic linked to IBD.
• Microbial anti-inflammatory molecule (MAM) is a key effector of F. duncaniae A2-165.
• Direct anti-inflammatory effects of purified MAM have not been previously evaluated.

Purpose of the Study:

• To produce and purify recombinant MAM (R-MAM).
• To evaluate the direct anti-inflammatory activity of R-MAM in vitro.
• To assess the protective effects of R-MAM in a murine model of intestinal inflammation.

Main Methods:

• Recombinant MAM (R-MAM) was produced and purified under denaturing conditions.
• In vitro assays were conducted using human intestinal epithelial cells (HT-29) and peripheral blood mononuclear cells (PBMCs).
• A DNBS-induced colitis murine model was used to evaluate in vivo efficacy.

Main Results:

• Purified R-MAM induced an anti-inflammatory cytokine profile in vitro.
• Oral administration of R-MAM significantly prevented weight loss in a colitis model.
• R-MAM reduced colon weight and thickness, indicating reduced inflammation.

Conclusions:

• The study validates the therapeutic potential of MAM for intestinal inflammation.
• R-MAM demonstrated direct anti-inflammatory activity despite purification under denaturing conditions.
• Future research should focus on optimizing protein stability for enhanced therapeutic efficacy.